ClinicalTrials.gg
CompletedNCT06238856Updated Feb 2, 2024

Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

A Phase 1 interventional study of SLIT™ Amikacin and Placebo in Cystic Fibrosis, sponsored by Insmed Incorporated. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2005, 21 years 9 months ago, and no results have been posted to the registry.
  • Registered 19 years 8 months after the study started (first participant enrolled May 2004, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.

02

Conditions studied

  • Cystic Fibrosis

Browse trials for

03

In context

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.

This study's enrollment of 18 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participants must produce sputum that is positive for Pseudomonas aeruginosa.
  • Confirmed diagnosis of CF (positive sweat chloride >60 milliequivalents (mEq)/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype.
  • (FEV1) ≥40% predicted at Screening as calculated by the Knudsen reference equations.
  • Clinically stable with no evidence of current pulmonary exacerbation.

Exclusion criteria

Exclusion Criteria:

  • History of lung transplantation.
  • Use of intravenous antibiotics or oral quinolones within 14 days of Screening.
  • Use of low dose oral antibiotics (e.g. tetracycline, sulfa) for acne or other conditions within 30 days of Screening.
  • Use of systemic (≥20 milligrams [mg] of prednisone per day) within 30 days of Screening.
  • Initiation of TOBI® (tobramycin), high dose ibuprofen, recombinant human DNase (rhDNase), or macrolide antibiotics within 60 days of Screening.
  • History of sputum or throat swab culture yielding Burkholderia cepacia complex within 2 years of Screening or growth of Burkholderia cepacia complex from the sputum or throat swab culture obtained at Screening.
  • History of biliary cirrhosis, portal hypertension, or splenomegaly or splenomegaly on physical exam at Screening or enrollment.
  • History of daily continuous oxygen supplementation or requirement for more than 2 liter per minute (L/min) at night.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1: Amikacin Dose 1 + Placebo

    Participants will receive a single dose of SLIT™ amikacin at Dose 1 or matching placebo by inhalation on Day 0.

    Drug: SLIT™ Amikacin · Drug: Placebo

  • Experimental
    Cohort 2: Amikacin Dose 2 + Placebo

    Participants will receive a single dose of SLIT™ amikacin at Dose 2 or matching placebo by inhalation on Day 0 upon initiation of Cohort 2.

    Drug: SLIT™ Amikacin · Drug: Placebo

  • Experimental
    Cohort 3: Amikacin Dose 3 + Placebo

    Participants will receive a single dose of SLIT™ amikacin at Dose 3 or matching placebo by inhalation on Day 0 upon initiation of Cohort 3.

    Drug: SLIT™ Amikacin · Drug: Placebo

Interventions

  • DrugSLIT™ Amikacin

    Amikacin administered via the Pari LC STAR™ nebulizer.

    Also known as: TR02

  • DrugPlacebo

    Nebulized saline.

06

What researchers measure

Primary outcomes

  1. Number of Participants who Experience a Treatment Emergent Adverse Event (TEAE)

    Safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.

    Time frame: Up to Day 28

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUC) of SLIT™ Amikacin in Serum

    Time frame: Pre-dose and at multiple time points post-dose up to Day 3

  2. Percent Dose of SLIT™ Amikacin in Urine

    Time frame: At multiple time points post-dose up to Day 3

  3. AUC of SLIT™ Amikacin in Sputum

    Time frame: Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 14, and 28

  4. Change From Baseline in Sputum Density of Pseudomonas Aeruginosa

    Time frame: Baseline up to Day 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in Feb 2005, 8 months.

Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 8 months is close to that.

Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 2, 2024
StartActual
May 12, 2004
Primary completionActual
Feb 8, 2005
CompletionActual
Feb 8, 2005
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238856
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
May 12, 2004
Primary completion
Feb 8, 2005
Completion
Feb 8, 2005
Last update
Feb 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion